Introduction {#s1}
============

Torsins belong to the AAA+ ([A]{.ul}TPases [a]{.ul}ssociated with a variety of cellular [a]{.ul}ctivities) ATPase family, a functionally diverse group of enzymes, which are fueled by ATP hydrolysis. AAA+ ATPases organize in structurally distinct fashions and interact with various accessory elements to remodel their protein or nucleic acid substrates ([@bib15]; [@bib54]; [@bib55]). Torsins are poorly understood AAA+ proteins with yet elusive functions and unknown substrates ([@bib32]; [@bib45]). Among the five human torsins (TorsinA, TorsinB, Torsin2A, Torsin3A and Torsin4A), neuronally expressed TorsinA carries the most clinical significance since it is at the root of primary dystonia. Primary dystonia is a devastating neuromuscular disease that is predominantly caused by the deletion of glutamate 302 or 303 (ΔE) in TorsinA ([@bib20]; [@bib44]). The etiology of primary dystonia is poorly understood ([@bib5]; [@bib22]), and there is currently no known cure for it.

TorsinA is an unusual AAA+ ATPase, because, unlike any other family member ([@bib15]; [@bib32]; [@bib45]; [@bib55]), it is localized to the endoplasmic reticulum (ER) and the contiguous perinuclear space (PNS), and because it is not self-activated, but instead needs the AAA+-like proteins [L]{.ul}amina-[a]{.ul}ssociated [p]{.ul}rotein 1 (LAP1) or [Lu]{.ul}minal domain [l]{.ul}ike [L]{.ul}AP1 (LULL1) to catalyze ATP hydrolysis ([@bib6]; [@bib35]; [@bib47]). LAP1 is a type-II transmembrane protein, which resides at the inner nuclear membrane (INM) through its association with the nuclear lamina ([@bib19]). LULL1 is a LAP1 paralog, which localizes to the outer nuclear membrane (ONM) and the continuous ER, with its N-terminal portion protruding into the cytoplasm ([@bib19]). The structurally similar luminal domains of LAP1/LULL1 interact with TorsinA, and they provide an arginine finger to the TorsinA active site to facilitate torsin's ATP hydrolysis ([@bib6]; [@bib47]). Arginine fingers are key structural motifs of AAA+ ATPases because they neutralize the transition state during ATP hydrolysis ([@bib54]). Since torsins lack arginine fingers themselves, this activation mechanism through LAP1/LULL1 is likely critical for their function. As reported by several labs, the disease mutant TorsinA ΔE is compromised in binding to LAP1/LULL1 ([@bib39]; [@bib57]; [@bib58]). Clearly, this suggests that a probable cause of primary dystonia is the lack of activation of TorsinA. In line with this suggestion, LAP1 deletion shows a similar phenotype to Torsin ΔE, and contributes to disease pathology ([@bib30]).

To investigate the molecular basis for primary dystonia as a result of the glutamate 302/303 deletion in TorsinA, we took a structural approach. We obtained high-resolution crystal structures of TorsinA as well as TorsinAΔE, each in complex with LULL1, using a nanobody as crystallization chaperone. These structures likely open a pathway toward rational, structure-based drug design against primary dystonia.

Results {#s2}
=======

TorsinA is a catalytically inactive AAA+ ATPase ([@bib6]; [@bib57]), notoriously ill-behaved *in vitro*, primarily due to its limited solubility and stability. We partially overcame these problems by stabilizing an ATP-trapped E171Q mutant of human TorsinA (residues 51--332) by co-expressing it with the luminal activation domain of human LULL1 (residues 233--470). This resulted in a better behaved heterodimeric complex ([Figure 1A](#fig1){ref-type="fig"}), which, however, was still recalcitrant to our crystallization efforts. To facilitate crystallization, we isolated a nanobody (VHH-BS2) from an alpaca immunized with the TorsinA~EQ~-LULL1 complex. A stable, heterotrimeric complex of TorsinA~EQ~-LULL1-VHH-BS2 was readily crystallized in the presence of ATP. We collected a 1.4 Å dataset and solved the structure by molecular replacement, using the LULL1-homolog LAP1 and a VHH template as search models ([@bib47]) (Materials and methods, [Table 1](#tbl1){ref-type="table"}). TorsinA~EQ~ adopts a typical AAA+ ATPase fold ([Figure 1B](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). The N-terminal nucleotide-binding or large domain (residues 55--271) is composed of a central five-stranded, parallel β-sheet surrounded by 8 α-helices. A small three-helix bundle at its C-terminus (residues 272--332), forms critical contacts with LULL1. An ATP molecule is bound in the manner characteristic of P-loop NTPases ([@bib54]). The Walker A and B motifs are positioned to mediate the requisite nucleotide interactions, with sensor 1 and sensor 2 regions sensing the γ-phosphate and thus the nucleotide state ([Figure 1C](#fig1){ref-type="fig"}). The luminal LULL1 activation domain (residues 236--470) adopts an AAA+-like conformation, very similar to its paralog LAP1 (rmsd 1.04 Å over 211 Cα positions, [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). The AAA+-like domain comprises a central β-sheet embedded within six α-helices ([Figure 1B](#fig1){ref-type="fig"}). A C-terminal small domain is not present. Similar to LAP1, an intramolecular disulfide bond forms at the C terminus of LULL1, between conserved residues C310 and C468 ([Figure 1---figure supplements 1](#fig1s1){ref-type="fig"},[3](#fig1s3){ref-type="fig"}). Characteristically, LULL1 lacks nucleotide binding due to the absence of Walker A and B motifs ([@bib47]). LULL1 forms a composite nucleotide-binding site with TorsinA by providing arginine residue 449 ('arginine finger') at the base of helix α5 ([Figure 1C](#fig1){ref-type="fig"}). The arginine finger activates ATP hydrolysis by TorsinA ([@bib6]; [@bib47]). The small domain of TorsinA, including helix α7 featuring glutamates 302 and 303, is intimately involved in LULL1 binding. Nanobody VHH-BS2 binds both TorsinA and LULL1 at a shallow groove ([Figure 1B](#fig1){ref-type="fig"}, [Figure 1---figure supplement 4](#fig1s4){ref-type="fig"}). Nanobodies contain three complementarity determining regions (CDRs), with CDR3 most often making critical contacts with the antigen ([@bib38]). Indeed, the long CDR3 of VHH-BS2 (residues 97--112) is the main binding element in the complex.10.7554/eLife.17983.003Figure 1.Architecture of the TorsinA-LULL1 complex.(**A**) Schematic diagrams of TorsinA and LULL1. Important residues and sequence motifs are indicated. The colored areas mark the crystallized segments. Large and small domains of TorsinA are colored in purple and pink, respectively. SS, signal sequence; H, hydrophobic region; TM, transmembrane helix. (**B**) Cartoon representation of the TorsinA-LULL1 complex in two orientations. Color-coding as in (**A**). A nanobody (VHH-BS2, grey; complementarity determining regions, red) was used as a crystallization chaperone. Numbers refer to secondary structure elements. (**C**) Close-up of the ATP binding site. Key residues are labeled. 2F~o~−F~c~ electron density contoured at 2σ displayed as grey mesh. (**D**) Close-up of the proximal cysteines 280 and 319 next to the adenine base of the bound ATP. 2F~o~−F~c~ electron density is contoured at 1σ. The cysteine pair adopts three alternate conformations, but remains reduced in all of them.**DOI:** [http://dx.doi.org/10.7554/eLife.17983.003](10.7554/eLife.17983.003)10.7554/eLife.17983.004Figure 1---figure supplement 1.Structural comparisons.(**A**) Human TorsinA-ATP (left) displayed as a cartoon, compared to the D2 domain of the double-ringed AAA+ ATPase ClpB-AMPPCP (right) from *Thermus thermophilus* ([@bib56]) (PDB code 4LJ9) in the same orientation. Important structure motifs are labeled. (**B**) Human LULL1 (orange) superposed on human LAP1 (grey, PDB code 4TVS), shown in two orientations. The one region of major structural difference is labeled (left). The disulfide bridge within LAP1/LULL1 is in yellow (right).**DOI:** [http://dx.doi.org/10.7554/eLife.17983.004](10.7554/eLife.17983.004)10.7554/eLife.17983.005Figure 1---figure supplement 2.Phylogenetic analysis of Torsins.Maximally diverged torsins are aligned. Secondary structure elements of human TorsinA are displayed above the alignment. Important sequence motifs are boxed. LULL1 contacts, red circles, conserved cysteines, yellow circles. Proximal cysteines 280 and 319 connected with a dashed yellow line. Asterisk denotes putative torsin homologs based on sequence analysis. hs, *Homo sapiens*; oa, *Ornithorhynchus anatinus*; gg, *Gallus gallus*; tr, *Takifugu rubripes*; dr, *Danio rerio*; nv, *Nematostella vectensis*; bf, *Branchiostoma floridae*; stp, *Strongylocentrotus purpuratus*; ci, *Ciona intestinalis*; ce, *Caenorhabditis elegans*; dm, *Drosophila melanogaster*; ta, *Trichoplax adherens*.**DOI:** [http://dx.doi.org/10.7554/eLife.17983.005](10.7554/eLife.17983.005)10.7554/eLife.17983.006Figure 1---figure supplement 3.Phylogenetic analysis of LAP1/LULL1.Maximally diverged LAP1 and LULL1 sequences are aligned. If not experimentally confirmed, sequences were assigned as LAP1 or LULL1 based on the presence of an N-terminal, extraluminal domain with basic signature, characteristic of LAP1. Secondary structure elements of human LULL1 are displayed above the alignment. The strictly conserved Arg-finger is boxed. TorsinA contacts, red circles, conserved cysteines, yellow circles. Disulfide bridge depicted as a yellow line. hs, *Homo sapiens*; oa, *Ornithorhynchus anatinus*; gg, *Gallus gallus*; tr, *Takifugu rubripes*; dr, *Danio rerio*; nv, *Nematostella vectensis*; bf, *Branchiostoma floridae*; stp, *Strongylocentrotus purpuratus*; ci, *Ciona intestinalis*; ce, *Caenorhabditis elegans*; dm, *Drosophila melanogaster*; ta, *Trichoplax adherens*.**DOI:** [http://dx.doi.org/10.7554/eLife.17983.006](10.7554/eLife.17983.006)10.7554/eLife.17983.007Figure 1---figure supplement 4.Nanobody interaction.The heterotrimeric TorsinA(ATP)-LULL1-VHH-BS2 complex is shown in two orientations. Nanobody and interacting secondary structure elements of TorsinA and LULL1 are shown in full color, non-interacting elements in faded colors. Complementarity determining region (CDR) loops in red. Insets show close-ups with important interacting residues labeled.**DOI:** [http://dx.doi.org/10.7554/eLife.17983.007](10.7554/eLife.17983.007)10.7554/eLife.17983.008Figure 1---figure supplement 5.Comparison of sequence motifs of AAA+ ATPases.Torsins and LAP1/LULL1 sequences are compared to the HCLR clade, the most similar branch within the AAA+ ATPase family ([@bib15]; [@bib24]). Sequential elements characteristic for each of the 3 groups are displayed as WebLogos ([@bib10]). Numbering refers to ClpB-D2 from *Thermus thermophilus* for the HCLR class, human TorsinA for Torsins, and human LULL1 for LAP1/LULL1. Grey bars indicate the characteristic motif or residue, surrounded by a few adjacent residues to emphasize the distinct conservation. All three groups have elements that can be used to distinguish them among each other. Since Torsins and LAP1/LULL1 lack a pore loop consensus sequence φφG (where φ denotes a bulky hydrophobic residue), putative pore loop areas have been determined structurally. Dashed grey bars indicate residues which can be structurally aligned to the pore loop motif of the closest HCLR AAA+ clade members.**DOI:** [http://dx.doi.org/10.7554/eLife.17983.008](10.7554/eLife.17983.008)10.7554/eLife.17983.009Table 1.X-ray data collection and refinement statistics.**DOI:** [http://dx.doi.org/10.7554/eLife.17983.009](10.7554/eLife.17983.009)TorsinA-LULL1~233-470~TorsinAΔE-LULL1~233-470~**PDB Code**5J1S5J1T**Data collection**Space groupP2~1~2~1~2~1~P2~1~2~1~2~1~Cell dimensions*a, b, c* (Å)75.7, 90.7, 105.175.4, 88.4, 105.3α, β, γ (°)90.0, 90.0, 90.090.0, 90.0, 90.0Resolution (Å)61--1.40 (1.45--1.40)^\*^68--1.40 (1.45--1.40)*R*~sym~0.06 (0.88)0.10 (1.98)R~pim~0.03 (0.43)0.03 (0.60)*I* / σ33.0 (1.5)30.8 (1.3)Completeness (%)94.7 (67.5)97.9 (96.5)Redundancy5.7 (4.4)12.4 (11.3)CC(1/2)1.00 (0.65)1.00 (0.58)**Refinement**Resolution (Å)61.4--1.4067.7--1.40No. reflections132956134333*R*~work~ / *R*~free~0.143/0.1880.148/0.177No. atoms58985927Protein52415244Ligand/ion3547Water622636*B* factors (Å^2^)Protein31.324.0Ligand/ion23.217.2Water43.133.6r.m.s. deviationsBond lengths (Å)0.0140.017Bond angles (°)1.251.71RamachandranFavored/allowed/outliers (%)98.0/1.7/0.098.6/1.4/0.0[^1]

AAA+ ATPases are organized into a number of structurally defined clades ([@bib15]; [@bib24]), distinguished by shared structural elements. Comparison with other AAA+ ATPase structures shows that TorsinA fits best into a clade that also contains the bacterial proteins HslU, ClpA/B, ClpX, and Lon (HCLR clade), all of which are involved in protein degradation or remodeling ([@bib15]). These AAA+ family members share a β-hairpin insertion that precedes the sensor-I region ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). TorsinA also contains this structural element, but it adopts a distinctly different orientation compared to other members of the clade; however, the pre-sensor I region may be affected by crystal packing in our structure. Two other distinct regions are present. The protein degrading or remodeling AAA+ ATPases all form hexameric rings with a central pore ([@bib23]; [@bib42]; [@bib55]). 'Pore loops' in each subunit, conserved elements positioned between strand β2 and helix α2, are critical for threading the protein substrates through the ring ([@bib46]). Torsins are devoid of a pore loop consensus motif ([Figure 1---figure supplements 2](#fig1s2){ref-type="fig"},[5](#fig1s5){ref-type="fig"}). TorsinA has two cysteines (Cys280, and Cys 319, which is part of the sensor-II motif), positioned near the adenine base of the ATP molecule ([Figure 1D](#fig1){ref-type="fig"}). These cysteines do not form a disulfide bridge in our structure. However, the conservation of Cys280 and the Gly-Cys-Lys sensor-II motif at position 318--320 ([Figure 1---figure supplements 2](#fig1s2){ref-type="fig"},[5](#fig1s5){ref-type="fig"}) indicates an important functional role. A redox activity as part of the ATPase cycle therefore seems highly likely, as has been previously speculated ([@bib59], [@bib58]).

The interaction of TorsinA with its ATPase activators LULL1 and LAP1 is of particular importance, as a prominent mutation causing primary dystonia\--the deletion of glutamate 302 or 303\--weakens these interactions ([@bib39]; [@bib57]; [@bib58]). But why and how? The TorsinA-LULL1 interface extends over an area of 1439 Å^2^. The main structural elements involved in this interaction are the nucleotide-binding region as well as the small domain of TorsinA, and helices α0, α2, α4 and α5 of LULL1 ([Figure 1](#fig1){ref-type="fig"}, [Figure 1---figure supplements 2](#fig1s2){ref-type="fig"},[3](#fig1s3){ref-type="fig"}, [Figure 2A](#fig2){ref-type="fig"}). The exact position of the small domain of TorsinA relative to the large domain is likely dictated by the sensor II motif, preceding α8, which directly contacts the γ-phosphate of ATP through Lys 320, thus serving as an anchor point. A switch to ADP presumably weakens this connection, such that the small domain would become more loosely attached to the large domain. This could explain the observed ATP-dependency of LAP1/LULL1 binding ([@bib19]; [@bib39]; [@bib57]; [@bib58]). Within the small domain, helix α7, the following loop, and the terminal helix α8 contain all the critical residues. Glutamate 302 and 303 are positioned at the very end of helix α7, and both are involved in TorsinA contacts. Specifically, Glu 303 forms a prominent charge interaction with Arg 276 of LULL1. TorsinA Lys113 -- LULL1 Glu385, TorsinA Asp316 - LULL1 Arg419, TorsinA Lys317 - LULL1 Glu415, TorsinA Asp327 - LULL1 Lys283 are additional charge interactions.10.7554/eLife.17983.010Figure 2.Analysis of the TorsinA-LULL1 interface.(**A**) Side-by-side comparison of TorsinA-ATP-LULL1 (left) and TorsinAΔE-ATP-LULL1 (right). Zoomed insets show the atomic details of the interactions between TorsinA/TorsinAΔE and LULL1, with a focus on the ΔE303 area. (**B** and **C**) Mutational analysis of the TorsinA-LULL1 interface. Substitution or deletion of residues involved in TorsinA-LULL1 binding were probed using a Ni-affinity co-purification assay with recombinant, bacterial-expressed protein. Only TorsinA is His-tagged. SDS-PAGE analysis is shown. Lack of binding is observed by the absence of complex (uncomplexed His-tagged TorsinA is insoluble). t, total lysate, e, Ni eluate. Asterisk denotes an unrelated contaminant.**DOI:** [http://dx.doi.org/10.7554/eLife.17983.010](10.7554/eLife.17983.010)10.7554/eLife.17983.011Figure 2---figure supplement 1.Structural mapping of mutations causing dystonia.All known point mutations and deletions that lead to dystonia are marked as green dots and shown in light green color, respectively, on the TorsinA-ATP-LULL1 structure. A modifier TorsinA mutation, D216H, is marked as a blue dot. The structural equivalent of the LAP1 missense mutation (E482A) is LULL1 E368A, marked as a green dot. See [Table 2](#tbl2){ref-type="table"} for an explanation of the likely structural consequence.**DOI:** [http://dx.doi.org/10.7554/eLife.17983.011](10.7554/eLife.17983.011)10.7554/eLife.17983.012Table 2.Dystonia mutations.**DOI:** [http://dx.doi.org/10.7554/eLife.17983.012](10.7554/eLife.17983.012)ProteinMutationStructural consequenceReferenceTorsinA∆E302/303Weakened LAP1/LULL1 binding([@bib44])TorsinA∆F323-Y328Weakened LAP1/LULL1 binding([@bib33])TorsinAR288QWeakened LAP1/LULL1 binding([@bib60])TorsinAF205IFolding problem([@bib7])TorsinAD194VChange to the conserved, noncatalytic interface([@bib9])TorsinA∆A14-P15Improper cellular targeting([@bib52])TorsinAE121KCharge inversion at the membrane proximal interface([@bib52])TorsinAV129IFolding problem([@bib11])TorsinAD216H (modifier)Surface change; consequence unclear([@bib27]; [@bib31])LAP1c.186deiG (p.E62fsTer25)Lack of the luminal activation domain of LAP1([@bib28])LAP1E482A\*Improper folding([@bib12])[^2]

To investigate the atomic details of the weakened binding of TorsinAΔE to LAP1/LULL1, and thus the molecular basis of primary dystonia, we made use of the observation that VHH-BS2 also stabilizes the TorsinA~EQ~ΔE(ATP)-LULL1 interaction. We were able to crystallize TorsinA~EQ~ΔE(ATP)-LULL1-VHH-BS2 and determine its structure at a resolution of 1.4 Å. Not surprisingly, the overall structure is almost identical to the wild-type protein (0.34 Å rmsd over 276 Cα atoms for TorsinA, 0.27 Å rmsd over 226 Cα atoms for LULL1), except for critical differences in the TorsinA-LULL1 interface ([Figure 2A](#fig2){ref-type="fig"}). The principal difference is that helix α7 is shortened due to the missing Glu 303, with a slight\--but significant\--restructuring of the loop that follows to establish the connection with helix α8. For future reference, we suggest renaming the ΔE mutation ΔE303, rather than ΔE302/303, since the position of Glu 302 is effectively unchanged. In the dystonia mutant, the TorsinA Glu 303 -- LULL1 Arg 276 charge interaction is lost, and the hydrogen-bonding network involving TorsinA Glu 302, Phe 306 and Arg312, as well as LULL1 Arg412 and Glu416 is disrupted ([Figure 2A](#fig2){ref-type="fig"}). To determine the importance of different TorsinA residues for LULL1 binding, we performed a co-purification assay ([Figure 2B,C](#fig2){ref-type="fig"}). His-tagged, ATP-trapped TorsinA~EQ~ (residues 51--332) and mutants thereof were recombinantly co-expressed with LULL1 (residues 233--470), but without VHH-BS2, in bacteria. Binding was tested in a co-purification assay using Ni-affinity. The Torsin~EQ~ΔE303 mutation abolishes binding in this assay, as expected ([Figure 2B](#fig2){ref-type="fig"}). Since unbound TorsinA~EQ~ is largely insoluble, absence of binding is not registered as an appearance of TorsinA~EQ~ alone, but rather as a lack of eluted protein complex altogether. Eliminating the salt bridge between TorsinA Glu303 and LULL1 Arg276 does not disrupt the TorsinA-LULL1 interaction ([Figure 2B](#fig2){ref-type="fig"}). However, ΔMet304 and ΔThr305 both phenocopy ΔE303 in abolishing LULL1 binding ([Figure 2C](#fig2){ref-type="fig"}). This is in full agreement with published *in vivo* data using similar mutants ([@bib18]). The intricate network of interactions of the α7-α8 loop of TorsinA is crucial for LULL1 binding. Since the ΔE mutation causes a local change within the small domain of TorsinA rather than protein misfolding, it may be possible to rescue binding by developing a small molecule that resurrects the weakened TorsinAΔE-LAP1/LULL1 interaction.

Although TorsinAΔE303 is the most prevalent mutation that causes primary dystonia, it is not the only one ([@bib32]; [@bib45]). We examined the structural consequence of all known mutations ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}, [Table 2](#tbl2){ref-type="table"}). Based on our structural data, we strongly predict that most mutations likely cause protein misfolding or they weaken or abolish LAP1/LULL1 binding. Conversely, the two dystonia-mutations found in LAP1 presumably affect torsin interaction. Our structural data, therefore, clearly support the hypothesis that improper torsin activation is the likely cause of primary dystonia ([@bib30]).

Discussion {#s3}
==========

The biological function of TorsinA remains enigmatic ([@bib21]; [@bib25]; [@bib34]; [@bib41], [@bib40]). Because TorsinA belongs to the AAA+ ATPase superfamily, with specific homology to the bacterial proteins HslU, ClpX, ClpA/B and Lon, it is generally assumed that TorsinA is involved in protein remodeling or protein degradation ([@bib32]; [@bib45]). However, a substrate of TorsinA has yet to be identified.

The TorsinA structure enables a more thorough comparison to other AAA+ ATPases, particularly with regard to the functionally relevant oligomerization state. After the discovery that LAP1/LULL1 are Arg-finger containing TorsinA activators with a AAA+-like structure, it seemed reasonable to suggest that TorsinA and LAP1/LULL1 likely form heterohexameric rings ((TorsinA-ATP-LAP1/LULL1)~3~) in order to function ([@bib6]; [@bib47]). However, the predominant oligomeric form of recombinant TorsinA-ATP-LAP1/LULL1 complex *in vitro* and in solution is the heterodimer ([@bib6]; [@bib47]). In addition, torsin variants have been reported to occur in various oligomeric forms as detected by Blue Native PAGE (BN-PAGE) ([@bib17]; [@bib26]; [@bib51]). Our structure now raises doubts about the physiological relevance of a heterohexameric ring ([Figure 3](#fig3){ref-type="fig"}). First, we note that the small domain of TorsinA is essential for LAP1/LULL1 binding ([Figure 2C](#fig2){ref-type="fig"}). This is reminiscent of the related HCLR AAA+ clade members where the small domain is known to be critical for hexamerization ([@bib4]; [@bib36]). The importance of the small domain for oligomerization in the context of torsins has also been discussed recently ([@bib45]). Neither LAP1 nor LULL1 harbor a small domain, arguing against formation of a stable heteromeric ring, or, alternatively, suggesting a ring of substantially different architecture. Second, ring formation is important for AAA+ ATPases that thread their protein substrate through a central pore for refolding or for degradation. This central pore is lined with conserved 'pore loops' that are essential for function ([@bib55]). Neither TorsinA and its homologs, nor LAP1/LULL1 have 'pore loop' equivalents ([Figure 1---figure supplement 5](#fig1s5){ref-type="fig"}). TorsinA is therefore unlikely to actually employ a peptide threading mechanism that involves a central pore. Third, the surface conservation of LAP1/LULL1 also argues against a heteromeric ring assembly. Although the catalytic, ATP-containing interface with TorsinA is well-conserved, the presumptive non-catalytic, nucleotide-free interface is not ([Figure 3B](#fig3){ref-type="fig"}). Importantly and in contrast to LAP1/LULL1, the same analysis for TorsinA shows that its 'backside' is conserved. TorsinA may therefore interact in homotypic fashion with TorsinA, with other torsin homologs, or even with an additional, yet unidentified protein. This could mean that the previously observed hexameric assemblies ([@bib17]; [@bib26]; [@bib47]) may only contain one LAP1/LULL1 unit, and multiple torsin units, a property that the employed assays would not have differentiated. It is also possible, that the reported hexameric assemblies reflect a vestigial, yet physiologically irrelevant property, perhaps just of the evolutionary origin of the Torsin-LAP1/LULL1 system. Taking all the existing data into account, it is suggestive that TorsinA may be an exceptional AAA+ ATPase in that it simply acts as a heterodimer, together with LAP1 or LULL1 functioning as an activator. As long as the biological function and the substrate for TorsinA are unclear, however, the physiologically relevant oligomeric state of TorsinA ultimately remains a matter of speculation. Given the unique properties of TorsinA, keeping an open mind about TorsinA assembly into its functional state is called for, as it may well differ more than anticipated from well-studied AAA+ ATPase systems.10.7554/eLife.17983.013Figure 3.Oligomerization of TorsinA-LULL1.(**A**) Left, Schematic representation of a hypothetical heterohexameric (TorsinA-LULL1)~3~ ring model, in analogy to canonical AAA+ ATPases. White star represents ATP. Since LULL1 cannot bind a nucleotide, there would be three catalytic (nucleotide-bound) and three non-catalytic interfaces per ring. Open-book representation of the catalytic interface between TorsinA and LULL1, as seen in this study. Black line marks the outline of the interface. Color gradient marks conservation across diverse eukaryotes. (**B**) The same analysis as in (**A**), but for the hypothetical 'non-catalytic' interface. The interface model on the right is based on swapping the TorsinA and LULL1 positions in the TorsinA-LULL1 complex.**DOI:** [http://dx.doi.org/10.7554/eLife.17983.013](10.7554/eLife.17983.013)

The observation that the nanobody VHH-BS2 stabilizes the TorsinAΔE303-LULL1 suggests that it could possibly be used directly as a therapeutic. After all, it could directly rescue TorsinA activity. There are, however, at least two major problems. First, VHH-BS2 only recognizes the TorsinA- (or TorsinAΔE303-) LULL1 complex, but not the homologous TorsinA-LAP1 complex. The function of LULL1 is still poorly understood, but a knockdown does not generate an NE blebbing phenotype ([@bib17]; [@bib49]; [@bib51]), which is symptomatic for a TorsinA knockout ([@bib20]) or a LAP1 knockdown ([@bib30]). Therefore, resurrecting activation of TorsinAΔE303 via LULL1 is unlikely to ameliorate the dystonia phenotype. Furthermore, the nanobody interaction site on the TorsinA-LULL1 interface is very likely oriented toward the ER membrane, which can be inferred from the relative positions of the membrane anchor of LULL1 and the hydrophobic, likely membrane-proximal N-terminal region of TorsinA. These topological restraints suggest that the nanobody will not bind *in vivo*, but that it is of significant use for *in vitro* studies.

Materials and methods {#s4}
=====================

Constructs, protein expression and purification {#s4-1}
-----------------------------------------------

DNA sequences encoding human TorsinA (residues 51--332) and the luminal domain of human LULL1 (residues 233--470) were cloned into a modified ampicillin resistant pETDuet-1 vector (EMD Millipore). TorsinA, N-terminally fused with a human rhinovirus 3C protease cleavable 10xHis-7xArg tag, was inserted into the first multiple cloning site (MCS), whereas the untagged LULL1 was inserted into the second MCS. Mutations on TorsinA and LULL1 were introduced by site-directed mutagenesis. The untagged VHH-BS2 nanobody was cloned into a separate, modified kanamycin resistant pET-30b(+) vector (EMD Biosciences).

To co-express TorsinA (EQ or EQ/ΔE), LULL1 and VHH-BS2 for crystallization, the *E. coli* strain LOBSTR(DE3) RIL (Kerafast, Boston MA) ([@bib3]) was co-transformed with the two constructs described above. Cells were grown at 37°C in lysogeny broth (LB) medium supplemented with 100 µg ml^−1^ ampicillin, 25µg ml^−1^ kanamaycin and 34 µg ml^−1^ chloramphenicol until an optical density (OD~600~) of 0.6--0.8 was reached, shifted to 18°C for 20 min, and induced overnight at 18°C with 0.2 mM isopropyl β-D-1-thiogalactopyranoside (IPTG). The bacterial cultures were harvested by centrifugation, suspended in lysis buffer (50 mM HEPES/NaOH pH 8.0, 400 mM NaCl, 40 mM imidazole, 10 mM MgCl~2~, and 1 mM ATP) and lysed with a cell disruptor (Constant Systems). The lysate was immediately mixed with 0.1 M phenylmethanesulfonyl fluoride (PMSF) (50 μl per 10 ml lysate) and 250 units of TurboNuclease (Eton Bioscience), and cleared by centrifugation. The soluble fraction was gently mixed with Ni-Sepharose 6 Fast Flow (GE Healthcare) resin for 30 min at 4°C. After washing with the lysis buffer, bound protein was eluted in elution buffer (10 mM HEPES/NaOH pH 8.0, 150 mM NaCl, 300 mM imidazole, 10 mM MgCl~2~, and 1 mM ATP). The eluted protein complex was immediately purified by size exclusion chromatography on a Superdex S200 column (GE Healthcare) equilibrated in running buffer (10 mM HEPES/NaOH pH 8.0, 150 mM NaCl, 10 mM MgCl~2~, and 0.5 mM ATP). Following the tag removal by 10xHis-7xArg-3C protease, the fusion tags and the protease were separated from the complex by cation-exchange chromatography on a HiTrapS column (GE Healthcare) using a linear NaCl gradient. The flow-through from the cation-exchange chromatography, containing the protein complex, was purified again by size exclusion chromatography on a Superdex S200 column as at the previous step.

For the non-structural analysis of TorsinA and LULL1 variants, the pETDuet-1-based expression plasmid was transformed into LOBSTR(DE3) RIL cells without co-expressing nanobody VHH-BS2. Ni^2+^-affinity purification was performed as described above and bound protein was eluted. Aliquots from the Ni^2+^-eluate and the total lysate were collected and analyzed by SDS-PAGE gel electrophoresis.

Crystallization {#s4-2}
---------------

Purified TorsinA~EQ~-LULL1-VHH-BS2 and TorsinA~EQ~ΔE-LULL1-VHH-BS2 complexes were concentrated up to 4--4.5 mg/ml and supplemented with 2 mM ATP prior to crystallization. The TorsinA~EQ~ containing complex crystallized in 13% (w/v) polyethylene glycol (PEG) 6000, 5% (v/v) 2-Methyl-2,4-pentanediol, and 0.1 M MES pH 6.5. The TorsinA~EQ~ΔE containing complex crystallized in 19% (w/v) PEG 3350, 0.2 M AmSO~4~, and 0.1 M Bis-Tris-HCl pH 6.5. Crystals of both complexes grew at 18°C in hanging drops containing 1 μl of protein and 1 μl of mother liquor. Clusters of diffraction quality, rod-shaped crystals formed within 3--5 days. Single crystals were briefly soaked in mother liquor supplemented with 20% (v/v) glycerol for cryoprotection and flash-frozen in liquid nitrogen.

Data collection and structure determination {#s4-3}
-------------------------------------------

X-ray data were collected at NE-CAT beamline 24-ID-C at Argonne National Laboratory. Data reduction was performed with the HKL2000 package ([@bib43]), and all subsequent data-processing steps were carried out using programs provided through SBGrid ([@bib37]). The structure of the TorsinA~EQ~-LULL1-VHH-BS2 complex was solved by molecular replacement (MR) using the Phaser-MR tool from the PHENIX suite ([@bib1]). A three-part MR solution was easily obtained using a sequential search for models of LULL1, VHH-BS2, and TorsinA. The LULL1 model was generated based on the published human LAP1 structure (PDB 4TVS, chain A), using the Sculptor utility of the PHENIX suite (LULL1~241--470~ and LAP1~356--583~ share 64% sequence identity). The VHH-BS2 model was based on VHH-BS1 (PDB 4TVS, chain a) after removing the complementarity determining regions (CDRs). The poly-Ala model of TorsinA was generated based on *E. coli* ClpA (PDB 1R6B) using the MODELLER tool of the HHpred server ([@bib48]). The asymmetric unit contains one TorsinA~EQ~-LULL1-VHH-BS2 complex. Iterative model building and refinement steps gradually improved the electron density maps and the model statistics. The stereochemical quality of the final model was validated by Molprobity ([@bib8]). TorsinA~EQ~ΔE-LULL1-VHH-BS2 crystallized in the same unit cell. Model building was carried starting from a truncated TorsinA~EQ~-LULL1-VHH-BS2 structure. All manual model building steps were carried out with Coot ([@bib14]), and *phenix.refine* was used for iterative refinement. Two alternate conformations of a loop in LULL1 (residues 428--438) were detected in the F~o~−F~c~ difference electron density maps of both structures, and they were partially built. For comparison, the cysteine residues of TorsinA at the catalytic site (residues 280 and 319 in the TorsinA~EQ~ structure) were built in the reduced and the oxidized states, respectively. Building them as oxidized, disulfide-bridged residues consistently produced substantial residual F~o~−F~c~ difference density, which disappeared assuming a reduced state. Statistical parameters of data collection and refinement are all given in [Table 1](#tbl1){ref-type="table"}. Structure figures were created in PyMOL (Schrödinger LLC).

Bioinformatic analysis {#s4-4}
----------------------

Torsin and LAP1/LULL1 sequences were obtained via PSI-BLAST ([@bib2]) and Backphyre searches ([@bib29]). Transmembrane domains were predicted using the HMMTOP tool ([@bib50]). LAP1/LULL1 proteins were distinguished based on the calculated isoelectric point (pI) of their extra-luminal portions. The intranuclear domain of LAP1 has a characteristically high pI of \~8.5--10 due to a clustering of basic residues, while the cytoplasmic domain of LULL1 is distinctively more acidic. Multiple sequence alignments were performed using MUSCLE ([@bib13]), and visualized by Jalview ([@bib53]). To illustrate evolutionary conservation on TorsinA and LULL1 surfaces, conservation scores for each residue were calculated using the ConSurf server with default parameters ([@bib16]).

The sequences, which were used to generate the multiple sequence alignments, were also used for preparing the sequence logos of Torsins and LAP1/LULL1 in [Figure 1---figure supplement 5](#fig1s5){ref-type="fig"}. To obtain the sequence logo of the HCLR clade AAA+ ATPases, *Escherichia coli* ClpA-D2 (residues 458--758), *Escherichia coli* ClpB-D2 (residues 568--857), *Bacillus subtilis* ClpE-D2 (residues 409--699), *Saccharomyces cerevisiae* Hsp104-D2 (residues 578--868), *Escherichia coli* HslU (residues 13--443), *Bacillus subtilis* HslU (residues 15--455), *Streptomyces coelicolor* ClpX (residues 71--409), *Drosophila melanogaster* ClpX (residues 199--634), *Escherichia coli* Lon (residues 320--580), *Caenorhabditis elegans* Lon (residues 476--771), *Thermus thermophilus* ClpB-D2 (residues 536--845), *Escherichia coli* ClpX (residues 64--403), *Helicobacter pylori* ClpX (residues 77--430), *Haemophilus influenza* HslU (1--444), *Bacillus subtilis* Lon (residues 300--590), *Bacillus subtilis* ClpC-D2 (residues 486--802), *Saccharomyces cerevisiae* Hsp78-D2 (residues 482--794) and *Arabidopsis thaliana* Hsp101-D2 (residues 547--849) sequences were used. All sequence logos were generated using WebLogo ([@bib10]).

Generation and selection of nanobodies {#s4-5}
--------------------------------------

The purified human TorsinA~EQ~-LULL1 complex was injected into a male alpaca (*Lama pacos*) for immunization. Generation and screening of nanobodies was carried out as previously described ([@bib47]). Each of the selected nanobodies was subcloned into a pET-30b(+) vector with a C-terminal His~6~-tag. Each nanobody was bacterially expressed and Ni^2+^-affinity purified essentially as described (see above). Different from the TorsinA-containing preparations, MgCl~2~ and ATP were eliminated from all buffer solutions. The Ni^2+^-eluate was purified via size exclusion chromatography on a Superdex S75 column (GE Healthcare) in running buffer (10 mM HEPES/NaOH pH 8.0, 150 mM NaCl). Nanobody binding was validated by size exclusion chromatography on a 10/300 Superdex S200 column in 10 mM HEPES/NaOH pH 8.0, 150 mM NaCl, 10 mM MgCl~2~ and 0.5 mM ATP. Equimolar amounts of TorsinA~EQ~-LULL1 and TorsinA~EQ~-LULL1-VHH were loaded and nanobody binding was monitored by a shift in the elution profile and via SDS-PAGE analysis. After validating VHH-BS2 interaction with TorsinA~EQ~-LULL1, the C-terminal His~6~-tag of VHH-BS2 was removed from the pET-30b(+) vector for co-purification experiments.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Structures of TorsinA and its dystonia-mutant in complex with an activator reveal the molecular basis for the disorder\" for consideration by *eLife*. Your article has been favorably evaluated by John Kuriyan (Senior editor) and three reviewers, one of whom, Wesley I Sundquist (Reviewer \#1), is a member of our Board of Reviewing Editors, and another is Christopher Hill (Reviewer \#3).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

The manuscript by Demircioglu et al. describes high resolution crystal structures of: 1) an \"E/Q\" (enzymatically inactive), but otherwise wild type TorsinA protein, in complex with its activator, LULL1, and 2) an analogous structure of the dystonia-causing \"delta E\" TorsinA protein in complex with LULL1. Strengths of the manuscript include the medical significance and scientific interest in TorsinA, and the importance for the field of knowing the precise structure of TorsinA and how it interacts with its activators. Two potentially important mechanistic implications of the study are: 1) TorsinA may not function as a hetero-hexamer (in contradiction to the prevailing model), and 2) the protein may be regulated by a redox mechanism via reversible formation of a disulfide bond between a pair of Cys residues located near the ATP binding site. Unfortunately, neither of these provocative proposals was proven definitively, and indeed the manuscript provides less mechanistic insight than would be ideal. Nevertheless, publication is warranted owing to: 1) the enzyme\'s importance (TorsinA has an intriguing, but poorly characterized role in nuclear membrane budding processes and it\'s mutations can cause dystonia), 2) the importance for the field of having a structural basis for understanding TorsinA and its interactions with activators (the results aren\'t entirely unexpected because donation of an activating Arg finger from the LULL1/LAP1 activators had been predicted, but having precise structures as an underpinning for further experimentation will be very helpful and could even guide the development of small molecules that could restore activator binding to the \"deltaE\" TorsinA mutants), and 3) the study will undoubtedly stimulate further work, including testing possible redox regulation and the possibility that TorsinA functions with activators as heterodimers (and not heterohexamers). The complex structure itself, together with the lack of conserved pore loop structures in TorsinA are quite consistent with this idea, but unfortunately the study isn\'t definitive because structure was determined in complex with a nanobody (which could have prevented oligomerization) and because the \"backside\" of Torsin A is conserved, so it remains possible that this surface interacts with other proteins (possibly even via homo-oligomerization with other TorsinA molecules). If a heterodimer is indeed the active minimal module, this would lend further credence to the concept that the TorsinA/LULL1 (and LAP1) complexes are \"hybrids\" between traditional ring AAA ATPases and G-protein/GAP systems.

The structures themselves are straightforward and are determined at high resolution. Ideally, the authors would test their provocative mechanistic proposals with additional biochemical analyses (beyond the rather rudimentary binding studies that are presented), but we are not requiring such studies owing to the absence of good in vitro assays or known substrates.

The discussion on the oligomeric state should be improved by including additional references. Specifically, it was previously published (Crit Rev Biochem Mol Biol. 2015;50([@bib5]):532-49) that the absence of the C-terminal subdomain in LULL1/LAP1 is difficult to reconcile with a closed, mixed ring conformation based on the requirement of the C-terminal four helix bundle in related Clp/HSP100 proteins. This should be explicitly stated, along with references reporting the requirement for the C-terminal subdomain in Clp ATPases. The authors should also include references reporting higher-order oligomeric assemblies of expressed Torsin, observed using Blue Native PAGE (Jungwirth et al. 2010; Goodchild et al. 2015). In this case, contributions of LAP1/LULL1 activators can be largely ignored. While these studies do not exclude the presence of additional cellular interaction partners, they do support the idea that Torsins can assemble into higher-order (\>\>2) homo-oligomeric assemblies, consistent with the conservation of possible Torsin-Torsin interfaces.
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Author response

*The manuscript by Demircioglu et al. describes high resolution crystal structures of: 1) an \"E/Q\" (enzymatically inactive), but otherwise wild type TorsinA protein, in complex with its activator, LULL1, and 2) an analogous structure of the dystonia-causing \"delta E\" TorsinA protein in complex with LULL1. Strengths of the manuscript include the medical significance and scientific interest in TorsinA, and the importance for the field of knowing the precise structure of TorsinA and how it interacts with its activators. Two potentially important mechanistic implications of the study are: 1) TorsinA may not function as a hetero-hexamer (in contradiction to the prevailing model), and 2) the protein may be regulated by a redox mechanism via reversible formation of a disulfide bond between a pair of Cys residues located near the ATP binding site. Unfortunately, neither of these provocative proposals was proven definitively, and indeed the manuscript provides less mechanistic insight than would be ideal. Nevertheless, publication is warranted owing to: 1) the enzyme\'s importance (TorsinA has an intriguing, but poorly characterized role in nuclear membrane budding processes and it\'s mutations can cause dystonia), 2) the importance for the field of having a structural basis for understanding TorsinA and its interactions with activators (the results aren\'t entirely unexpected because donation of an activating Arg finger from the LULL1/LAP1 activators had been predicted, but having precise structures as an underpinning for further experimentation will be very helpful and could even guide the development of small molecules that could restore activator binding to the \"deltaE\" TorsinA mutants), and 3) the study will undoubtedly stimulate further work, including testing possible redox regulation and the possibility that TorsinA functions with activators as heterodimers (and not heterohexamers). The complex structure itself, together with the lack of conserved pore loop structures in TorsinA are quite consistent with this idea, but unfortunately the study isn\'t definitive because structure was determined in complex with a nanobody (which could have prevented oligomerization) and because the \"backside\" of Torsin A is conserved, so it remains possible that this surface interacts with other proteins (possibly even via homo-oligomerization with other TorsinA molecules). If a heterodimer is indeed the active minimal module, this would lend further credence to the concept that the TorsinA/LULL1 (and LAP1) complexes are \"hybrids\" between traditional ring AAA ATPases and G-protein/GAP systems.*

*The structures themselves are straightforward and are determined at high resolution. Ideally, the authors would test their provocative mechanistic proposals with additional biochemical analyses (beyond the rather rudimentary binding studies that are presented), but we are not requiring such studies owing to the absence of good in vitro assays or known substrates.*

*The discussion on the oligomeric state should be improved by including additional references. Specifically, it was previously published (Crit Rev Biochem Mol Biol. 2015;50([@bib5]6):532-49) that the absence of the C-terminal subdomain in LULL1/LAP1 is difficult to reconcile with a closed, mixed ring conformation based on the requirement of the C-terminal four helix bundle in related Clp/HSP100 proteins. This should be explicitly stated, along with references reporting the requirement for the C-terminal subdomain in Clp ATPases. The authors should also include references reporting higher-order oligomeric assemblies of expressed Torsin, observed using Blue Native PAGE (Jungwirth et al. 2010; Goodchild et al. 2015). In this case, contributions of LAP1/LULL1 activators can be largely ignored. While these studies do not exclude the presence of additional cellular interaction partners, they do support the idea that Torsins can assemble into higher-order (\>\>2) homo-oligomeric assemblies, consistent with the conservation of possible Torsin-Torsin interfaces.*

We have revisited the existing literature and have rephrased this part of the discussion accordingly.

[^1]: ^\*^Values in parentheses are for highest-resolution shell. One crystal was used for each dataset.

[^2]: \*Assesment based on the equivalent residue in LULL1 (E368).
